Effect of Different Injection Regimens of Autologous Conditioned Plasma for Knee Osteoarthritis
Status:
Enrolling by invitation
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The clinical efficacy of hyaluronic acid or corticosteroid injections has been reported, but
effects are short lived. This has led to the development of additional injection options such
as autologous derived blood products which have been documented to alleviate symptoms related
to knee osteoarthritis, with recent comparative studies suggesting a greater, long-lasting
effect with these blood derived products like platelet rich plasma (PRP) [2-8]. One
clinically-developed preparation of platelet rich plasma, named autologous conditioned plasma
(ACP), has randomized controlled trial data proving efficacy [4,9]. Clinical use of platelet
rich plasma for knee arthritis typically involves a 3-injection series over 3 weeks, i.e. an
injection once a week for three weeks. The main objective of this study is to determine if
hyaluronic acid (HA) injected at the same time as autologous conditioned plasma (ACP), a
leukocyte-poor platelet rich plasma product, will improve the performance of ACP in the
treatment of symptomatic knee osteoarthritis. It is hypothesized that the injection of
hyaluronic acid will improve the efficacy of ACP.